CRISPR Therapeutics AG (0VRQ)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 51.32 |
|---|---|
| 52-week range | 44.30 – 63.43 |
| Return, 1 month / 3 months | −5.9% / +8.7% |
| Return, 1 year / 3 years | – / – |
| Trend | Below its 200-day average |
| RSI (14) | 48 |
| Volatility (1 year) | 52.8% |
| Worst drawdown (1 year) | -26.1% |
| Average daily value traded | 0.30M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CRISPR Therapeutics is a biopharmaceutical company that develops gene-based medicines using gene editing technology. Its work focuses on treatments for serious diseases, including inherited blood disorders, cancer and other conditions, through programs that modify genes in patients' cells. The company carries out research and clinical development and works with partners on manufacturing and commercialization. It is based in Zug, Switzerland, and also has research operations in the United States.
CRISPR Therapeutics AG trades under the code 0VRQ on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CRISPR Therapeutics AG (0VRQ) trades on the London Stock Exchange in UK. It last closed at USD 51.32 on 27 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 2,143 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.1% | ||
| From 52-week high | -17.2% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.7% | ||
| 6-month return | -0.6% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 41 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.1% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.30M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | −5.9% |
| 3 months | +8.7% |
| 6 months | −0.6% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 54.37 / 52.94 |
|---|---|
| Golden / death cross (60 days) | Golden, 23 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.75 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.